Tax Systems Launches AI-powered, SaaS Solution for Global Pillar Two Compliance and Reporting
15.1.2025 09:00:00 CET | Business Wire | Press release
Secure, scalable software that ensures organisations are prepared for the challenges of OECD Pillar Two rules now and in the future
Tax Systems, the global multi-tax compliance SaaS provider, has today announced the availability of Pillar2, an intuitive solution to de-risk and simplify compliance with the OECD’s global Pillar Two tax rules. Designed for organisations operating across multiple jurisdictions - Pillar2 will save businesses valuable time and reduce the risk of errors, so they can cost effectively operationalise Pillar Two reporting and comply with confidence.
Pillar2 integrates seamlessly with the provisioning and country-by-country reporting applications on TaxSuite - Tax Systems’ modular platform for international tax compliance. This means organisations can upload information once and re-use it as a single source of truth for their tax compliance data - helping to ensure consistency and accuracy across the tax reporting cycle and strengthen tax control frameworks.
The solution offers a range of innovative features, including a jurisdiction implementation tracker that shows if QDMTT, IIR, or UTPR are in force - this is kept up-to-date by Tax Systems, making it easy for organisations to know which rules are applied, and saving them the need to constantly monitor for changes. The offsets and allocations process is automated, with calculations that can’t be overridden, to further de-risk Pillar Two compliance. A comprehensive audit trail logging all user actions and data changes ensures complete transparency.
In addition to offering robust compliance support, Pillar2's flexible data management means it’s easy to upload information from both centralised systems and local operations, saving time, optimising processes and reducing the risk of errors.
Generative AI capabilities within Pillar2 also gives real-time tax insights, helping professionals to proactively manage risks and optimise their tax processes. Users can ask questions about their Pillar Two numbers, using natural language, receiving instant, data-driven responses. This approach makes it easy to identify and investigate any anomalies, while improving tax-related decision-making.
"Pillar Two compliance has added further complexity to tax professionals’ already heavy workloads, but our solution can take some of the burden by calculating any top-up tax due accurately and efficiently,” said Bruce Martin, CEO of Tax Systems. “Pillar2 has been designed from the ground up to help organisations meet these new global tax reporting requirements, simplify compliance processes and provide useful insights. Armed with the ability to manage their entire tax control framework from a single, fully connected platform, organisations can significantly reduce operational complexity while ensuring accuracy in every step of the compliance process.”
Improved collaboration backed by robust security
Pillar2 also supports organisations wishing to take advantage of co-sourcing - its SaaS capabilities, including role-based access control, ensure that only the right people can access sensitive tax data. This means that multi-nationals can maintain a level of control and collaborate with their advisors on different elements of the Pillar Two process using the same solution and data; rather than outsourcing their entire Pillar Two process.
Furthermore, all data is stored securely in MS Azure with a full audit trail, in keeping with being ISO27001 certified. Based on an organisation’s preference, Pillar2 can be configured for data to be hosted in either the UK or EEA.
“We have created a solution that is fit for purpose now and in the future, ensuring compliance with regulations and legislation as it changes both globally and locally,” concludes Bruce Martin. “The tax logic and calculations in Pillar2 have been built by the same team that supports Alphatax – the number 1 corporation tax compliance software in the UK, Ireland, and UAE. This is the latest solution on our global tax compliance and reporting platform and we’re excited for what is still to come. Tax compliance is always evolving and growing in complexity, and we are committed to advancing tax technology and supporting the global tax digitisation agenda.”
To learn more about Pillar2, click here.
About Tax Systems
Tax Systems, a Bowmark Capital-backed investment, is a global multi-tax compliance SaaS provider, with market-leading solutions across the UK, Ireland, Europe and the UAE. Its solutions digitise tax processes and revolutionise compliance operations, enabling tax professionals to create better opportunities and generate valuable insights from their tax function while also mitigating risk. Translating complex, ever-changing tax legislation into intuitive solutions, customers can trust that their calculations will be right, first-time, every time.
Founded in 1991, Tax Systems has over 30 years’ experience and works with over 42% of the FTSE 100 and 80% of the top advisory firms in the UK and Ireland, where more than 30,000 tax professionals are trained to use their solutions, filing over 200,000 submissions every year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250115190834/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom